Prognostic Significance of In-hospital Acquired Thrombocytopenia in Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention.
This large cohort study aimed to investigate the effect of acquired thrombocytopenia on the prognosis of patients with stable coronary artery disease undergoing percutaneous coronary intervention (PCI). Patients with stable coronary artery disease undergoing elective PCI were prospectively enrolled during 2013. All patients were followed for a median of 30 months (the 25th and 75th percentiles for follow-up time were 27 and 32 months). After excluding patients with baseline thrombocytopenia (<150 × 109/L), in-hospital acquired thrombocytopenia was defined as lowest platelet count <150 × 109/L or a relative reduction of 50% from the preoperative baseline platelet count after PCI. A total of 3,614 patients were enrolled; 329 (7.8%) patients developed thrombocytopenia after PCI. Analyses showed no difference in adverse events between groups during hospitalization, while long-term all-cause mortality, minor bleeding and major bleeding were significantly higher in patients with thrombocytopenia than in the control group. After multivariable adjustment, thrombocytopenia remained an independent risk factor for long-term all-cause mortality (HR 2.782, 95% CI 1.182-6.552, P = 0.019), minor bleeding (HR 2.198, 95% CI 1.217-3.972, P = 0.009) and major bleeding (HR 5.409, 95% CI 1.541-8.999, P = 0.008). Predictors of acquired thrombocytopenia were age, body mass index, baseline platelet count and left ventricular ejection fraction. Acquired thrombocytopenia may predict long-term all-cause mortality and bleeding events in patients with stable coronary artery disease who receive elective PCI.